All participants in the prescription drug supply chain deserve scrutiny, but weakening the mechanisms that extract price concessions will not lower drug spending. The more likely outcomes are gains for drug companies and less efficient pharmacies, and higher drug costs. Effects will be especially felt by seniors on Medicare and by smaller employers that lack the leverage to offset the law’s new constraints.
Copyright © 1997-2026 by www.people.com.cn all rights reserved
。关于这个话题，体育直播提供了深入分析
FT Digital Edition: our digitised print edition
17-летнюю дочь Николь Кидман высмеяли в сети за нелепую походку на модном показе20:47
Israeli military says it has begun a new wave of strikes on Tehran